Details of the Drug

General Information of Drug (ID: DMIZ6W2)

Drug Name

Norfloxacin

Synonyms

Baccidal; Barazan; Chibroxin; Fulgram; Lexinor; NFLX; Norflo; Norfloxacine; Norfloxacino; Norfloxacinum; Noroxin; Sebercim; Merck Brand of Norfloxacin; Norfloxacin Merck Brand; AM 0715; AM 715; AM0715; MK 0366; MK 366; MK0366; MK366; AM-0715; AM-715; Chibroxin (TN); Insensye (TN); MK-0366; MK-366; Norflohexal (TN); Norfloxacine [INN-French]; Norfloxacino [INN-Spanish]; Norfloxacinum [INN-Latin]; Norfocin (TN); Noroxin (TN); Nufloxib (TN); Roxin (TN); Utin (TN); Utinor (TN); Apo-Norflox (TN); Norfloxacin (JP15/USP/INN); Norfloxacin [USAN:BAN:INN:JAN]; Chibroxin, MK-366, Baccidal, Sebercim, Zoroxin, Norfloxacin; 1,4-Dihydro-1-ethyl-6-fluoro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid; 1-Ethyl-6-fluor-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-chinolincarbonsaeure; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-[1-piperazinyl]-3-quinoline-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydroquinoline-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid

Indication

Disease Entry	ICD 11	Status	REF
Acute gonococcal cervicitis	N.A.	Approved	[1]
Acute maxillary sinusitis	N.A.	Approved	[1]
Anthrax	1B97	Approved	[1]
Bacillary dysentery	1A02	Approved	[1]
Bacterial infection	1A00-1C4Z	Approved	[2]
Bronchitis	CA20	Approved	[1]
Chancroid	N.A.	Approved	[1]
Chronic tubotympanic suppurative otitis media	N.A.	Approved	[1]
Cystitis	GC00	Approved	[1]
Endomyometritis	N.A.	Approved	[1]
Malignant otitis externa caused by Pseudomonas aeruginosa	N.A.	Approved	[1]
Mycoplasma pneumoniae pneumonia	N.A.	Approved	[1]
Peritonitis	N.A.	Approved	[1]
Pneumonia	CA40	Approved	[1]
Prostatitis	N.A.	Approved	[1]
Pyelonephritis	N.A.	Approved	[1]
Staphylococcal pneumonia	N.A.	Approved	[1]
Staphylococcus aureus infection	N.A.	Approved	[1]
Streptococcal pneumonia	N.A.	Approved	[1]
Traveler's diarrhea	ME05.1	Approved	[1]
Urinary tract infection	GC08	Approved	[1]
Pneumonia caused by chlamydia	N.A.	Investigative	[1]
Pneumonia due to Klebsiella pneumoniae	CA40.03	Investigative	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Therapeutic Class

Antibiotics

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

319.33

Logarithm of the Partition Coefficient (xlogp)

-1

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption: The drug is rapidly absorbed []
Half-life: The concentration or amount of drug in body reduced by one-half in 3 - 4 hours [3]
Metabolism: The drug is metabolized via the liver []

Chemical Identifiers

Formula: C16H18FN3O3
IUPAC Name: 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid
Canonical SMILES: CCN1C=C(C(=O)C2=CC(=C(C=C21)N3CCNCC3)F)C(=O)O
InChI: InChI=1S/C16H18FN3O3/c1-2-19-9-11(16(22)23)15(21)10-7-12(17)14(8-13(10)19)20-5-3-18-4-6-20/h7-9,18H,2-6H2,1H3,(H,22,23)
InChIKey: OGJPXUAPXNRGGI-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 4539
ChEBI ID: CHEBI:100246
CAS Number: 70458-96-7
DrugBank ID: DB01059
TTD ID: D0Q2PE
VARIDT ID: DR01204
INTEDE ID: DR1176
ACDINA ID: D00479

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Bacterial DNA gyrase (Bact gyrase)	TTN6J5F	GYRA_STAAU ; GYRB_STAAU	Modulator	[4]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Organic anion transporting polypeptide 1A2 (SLCO1A2)	DTE2B1D	SO1A2_HUMAN	Substrate	[5]
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[6]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[7]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 1A2 (CYP1A2)_{Main DME}	DEJGDUW	CP1A2_HUMAN	Substrate	[8]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Apoptosis regulator BAX (BAX)	OTAW0V4V	BAX_HUMAN	Gene/Protein Processing	[9]
Apoptosis regulator Bcl-2 (BCL2)	OT9DVHC0	BCL2_HUMAN	Gene/Protein Processing	[9]
Apoptosis-inducing factor 1, mitochondrial (AIFM1)	OTKPWB7Q	AIFM1_HUMAN	Gene/Protein Processing	[9]
Bcl2-associated agonist of cell death (BAD)	OT63ERYM	BAD_HUMAN	Gene/Protein Processing	[9]
Caspase-2 (CASP2)	OTUDYSPP	CASP2_HUMAN	Gene/Protein Processing	[9]
Caspase-8 (CASP8)	OTA8TVI8	CASP8_HUMAN	Gene/Protein Processing	[9]
Collagenase 3 (MMP13)	OTY8BZIE	MMP13_HUMAN	Gene/Protein Processing	[10]
Major histocompatibility complex class I-related gene protein (MR1)	OTZU3XX7	HMR1_HUMAN	Gene/Protein Processing	[11]
Potassium voltage-gated channel subfamily H member 2 (KCNH2)	OTZX881H	KCNH2_HUMAN	Protein Interaction/Cellular Processes	[12]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Norfloxacin

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Clarithromycin	DM4M1SG	Moderate	Increased risk of prolong QT interval by the combination of Norfloxacin and Clarithromycin.	Bacterial infection [1A00-1C4Z]	[13]
-----------

Coadministration of a Drug Treating the Disease Different from Norfloxacin (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Norfloxacin and Ivosidenib.	Acute myeloid leukaemia [2A60]	[14]
Midostaurin	DMI6E0R	Moderate	Increased risk of prolong QT interval by the combination of Norfloxacin and Midostaurin.	Acute myeloid leukaemia [2A60]	[13]
Idarubicin	DMM0XGL	Moderate	Increased risk of prolong QT interval by the combination of Norfloxacin and Idarubicin.	Acute myeloid leukaemia [2A60]	[13]
Arn-509	DMT81LZ	Moderate	Increased risk of prolong QT interval by the combination of Norfloxacin and Arn-509.	Acute myeloid leukaemia [2A60]	[15]
Gilteritinib	DMTI0ZO	Moderate	Increased risk of prolong QT interval by the combination of Norfloxacin and Gilteritinib.	Acute myeloid leukaemia [2A60]	[16]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Norfloxacin and Ivabradine.	Angina pectoris [BA40]	[15]
Bepridil	DM0RKS4	Major	Increased risk of prolong QT interval by the combination of Norfloxacin and Bepridil.	Angina pectoris [BA40]	[17]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Norfloxacin and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[18]
Cilostazol	DMZMSCT	Moderate	Increased risk of prolong QT interval by the combination of Norfloxacin and Cilostazol.	Arterial occlusive disease [BD40]	[13]
Posaconazole	DMUL5EW	Moderate	Increased risk of prolong QT interval by the combination of Norfloxacin and Posaconazole.	Aspergillosis [1F20]	[13]
Levalbuterol	DM5YBO1	Moderate	Increased risk of ventricular arrhythmias by the combination of Norfloxacin and Levalbuterol.	Asthma [CA23]	[19]
Pirbuterol	DMI5678	Moderate	Increased risk of ventricular arrhythmias by the combination of Norfloxacin and Pirbuterol.	Asthma [CA23]	[19]
Aminophylline	DML2NIB	Moderate	Decreased metabolism of Norfloxacin caused by Aminophylline mediated inhibition of CYP450 enzyme.	Asthma [CA23]	[20]
Lisdexamfetamine	DM6W8V5	Moderate	Increased risk of prolong QT interval by the combination of Norfloxacin and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[15]
Desipramine	DMT2FDC	Moderate	Increased risk of prolong QT interval by the combination of Norfloxacin and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[13]
Retigabine	DMGNYIH	Moderate	Increased risk of prolong QT interval by the combination of Norfloxacin and Retigabine.	Behcet disease [4A62]	[21]
Lomustine	DMMWSUL	Minor	Decreased absorption of Norfloxacin due to intestinal mucosa variation caused by Lomustine.	Brain cancer [2A00]	[22]
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of Norfloxacin and Eribulin.	Breast cancer [2C60-2C6Y]	[23]
Lapatinib	DM3BH1Y	Moderate	Increased risk of prolong QT interval by the combination of Norfloxacin and Lapatinib.	Breast cancer [2C60-2C6Y]	[13]
Thiotepa	DMIZKOP	Minor	Decreased absorption of Norfloxacin due to intestinal mucosa variation caused by Thiotepa.	Breast cancer [2C60-2C6Y]	[22]
Bosutinib	DMTI8YE	Moderate	Increased risk of prolong QT interval by the combination of Norfloxacin and Bosutinib.	Breast cancer [2C60-2C6Y]	[15]
PF-04449913	DMSB068	Moderate	Increased risk of prolong QT interval by the combination of Norfloxacin and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[24]
Olodaterol	DM62B78	Moderate	Increased risk of ventricular arrhythmias by the combination of Norfloxacin and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[25]
Arformoterol	DMYM974	Moderate	Increased risk of ventricular arrhythmias by the combination of Norfloxacin and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[25]
Capecitabine	DMTS85L	Minor	Decreased absorption of Norfloxacin due to intestinal mucosa variation caused by Capecitabine.	Colorectal cancer [2B91]	[22]
Isoproterenol	DMK7MEY	Moderate	Increased risk of ventricular arrhythmias by the combination of Norfloxacin and Isoproterenol.	Conduction disorder [BC63]	[19]
Mestranol	DMG3F94	Moderate	Decreased absorption of Norfloxacin due to formation of complexes caused by Mestranol.	Contraceptive management [QA21]	[26]
Halothane	DM80OZ5	Moderate	Increased risk of prolong QT interval by the combination of Norfloxacin and Halothane.	Corneal disease [9A76-9A78]	[13]
Sevoflurane	DMC9O43	Moderate	Increased risk of prolong QT interval by the combination of Norfloxacin and Sevoflurane.	Corneal disease [9A76-9A78]	[23]
Probucol	DMVZQ2M	Moderate	Increased risk of prolong QT interval by the combination of Norfloxacin and Probucol.	Coronary atherosclerosis [BA80]	[21]
Oxtriphylline	DMLHSE3	Moderate	Decreased metabolism of Norfloxacin caused by Oxtriphylline mediated inhibition of CYP450 enzyme.	Cough [MD12]	[27]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Norfloxacin and Pasireotide.	Cushing syndrome [5A70]	[23]
Osilodrostat	DMIJC9X	Moderate	Increased risk of prolong QT interval by the combination of Norfloxacin and Osilodrostat.	Cushing syndrome [5A70]	[14]
Sertraline	DM0FB1J	Moderate	Increased risk of prolong QT interval by the combination of Norfloxacin and Sertraline.	Depression [6A70-6A7Z]	[13]
Escitalopram	DMFK9HG	Major	Increased risk of prolong QT interval by the combination of Norfloxacin and Escitalopram.	Depression [6A70-6A7Z]	[23]
Clomipramine	DMINRKW	Moderate	Increased risk of prolong QT interval by the combination of Norfloxacin and Clomipramine.	Depression [6A70-6A7Z]	[13]
Doxepin	DMPI98T	Moderate	Increased risk of prolong QT interval by the combination of Norfloxacin and Doxepin.	Depression [6A70-6A7Z]	[13]
Tetrabenazine	DMYWQ0O	Moderate	Increased risk of prolong QT interval by the combination of Norfloxacin and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[23]
Deutetrabenazine	DMUPFLI	Moderate	Increased risk of prolong QT interval by the combination of Norfloxacin and Deutetrabenazine.	Dystonic disorder [8A02]	[28]
Ingrezza	DMVPLNC	Moderate	Increased risk of prolong QT interval by the combination of Norfloxacin and Ingrezza.	Dystonic disorder [8A02]	[29]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Norfloxacin caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[15]
Solifenacin	DMG592Q	Moderate	Increased risk of prolong QT interval by the combination of Norfloxacin and Solifenacin.	Functional bladder disorder [GC50]	[13]
Sunitinib	DMCBJSR	Moderate	Increased risk of prolong QT interval by the combination of Norfloxacin and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[13]
Procarbazine	DMIK367	Minor	Decreased absorption of Norfloxacin due to intestinal mucosa variation caused by Procarbazine.	Hodgkin lymphoma [2B30]	[22]
Fostemsavir	DM50ILT	Moderate	Increased risk of prolong QT interval by the combination of Norfloxacin and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[30]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Norfloxacin and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[31]
Lopinavir	DMITQS0	Moderate	Increased risk of prolong QT interval by the combination of Norfloxacin and Lopinavir.	Human immunodeficiency virus disease [1C60-1C62]	[23]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of prolong QT interval by the combination of Norfloxacin and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[13]
Bempedoic acid	DM1CI9R	Major	Increased risk of tendinitis/tendon rupture by the combination of Norfloxacin and Bempedoic acid.	Hyper-lipoproteinaemia [5C80]	[32]
Melatonin	DMKWFBT	Minor	Decreased metabolism of Norfloxacin caused by Melatonin mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[21]
Tasimelteon	DMLOQ1V	Moderate	Decreased metabolism of Norfloxacin caused by Tasimelteon mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[33]
Iron	DMAP8MV	Moderate	Decreased absorption of Norfloxacin due to formation of complexes caused by Iron.	Iron deficiency anaemia [3A00]	[34]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Norfloxacin and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[23]
Phenolphthalein	DM5SICT	Moderate	Increased risk of ventricular arrhythmias by the combination of Norfloxacin and Phenolphthalein.	Irritable bowel syndrome [DD91]	[21]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Norfloxacin and Crizotinib.	Lung cancer [2C25]	[35]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Norfloxacin and Ceritinib.	Lung cancer [2C25]	[23]
Lurbinectedin	DMEFRTZ	Minor	Decreased absorption of Norfloxacin due to intestinal mucosa variation caused by Lurbinectedin.	Lung cancer [2C25]	[22]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Norfloxacin and Osimertinib.	Lung cancer [2C25]	[36]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Norfloxacin and Selpercatinib.	Lung cancer [2C25]	[37]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Norfloxacin and Lumefantrine.	Malaria [1F40-1F45]	[21]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Norfloxacin and Halofantrine.	Malaria [1F40-1F45]	[21]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Norfloxacin and Hydroxychloroquine.	Malaria [1F40-1F45]	[38]
Primaquine	DMWQ16I	Moderate	Increased risk of prolong QT interval by the combination of Norfloxacin and Primaquine.	Malaria [1F40-1F45]	[13]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of prolong QT interval by the combination of Norfloxacin and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[15]
Fludarabine	DMVRLT7	Minor	Decreased absorption of Norfloxacin due to intestinal mucosa variation caused by Fludarabine.	Malignant haematopoietic neoplasm [2B33]	[22]
Arsenic trioxide	DM61TA4	Major	Increased risk of ventricular arrhythmias by the combination of Norfloxacin and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[39]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Norfloxacin and Vemurafenib.	Melanoma [2C30]	[23]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of Norfloxacin and LGX818.	Melanoma [2C30]	[40]
Lanthanum carbonate	DMMJQSH	Moderate	Decreased absorption of Norfloxacin due to formation of complexes caused by Lanthanum carbonate.	Mineral absorption/transport disorder [5C64]	[23]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Norfloxacin and Panobinostat.	Multiple myeloma [2A83]	[41]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Norfloxacin and Siponimod.	Multiple sclerosis [8A40]	[21]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Norfloxacin and Fingolimod.	Multiple sclerosis [8A40]	[23]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Norfloxacin and Ozanimod.	Multiple sclerosis [8A40]	[42]
Deflazacort	DMV0RNS	Major	Increased risk of tendinitis/tendon rupture by the combination of Norfloxacin and Deflazacort.	Muscular dystrophy [8C70]	[43]
Romidepsin	DMT5GNL	Moderate	Increased risk of prolong QT interval by the combination of Norfloxacin and Romidepsin.	Mycosis fungoides [2B01]	[21]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Norfloxacin and Nilotinib.	Myeloproliferative neoplasm [2A20]	[23]
Dasatinib	DMJV2EK	Moderate	Increased risk of prolong QT interval by the combination of Norfloxacin and Dasatinib.	Myeloproliferative neoplasm [2A20]	[13]
Promethazine	DM6I5GR	Moderate	Increased risk of prolong QT interval by the combination of Norfloxacin and Promethazine.	Nausea/vomiting [MD90]	[13]
Bupropion	DM5PCS7	Major	Increased risk of lowers seizure threshold by the combination of Norfloxacin and Bupropion.	Nicotine use disorder [6C4A]	[44]
Entrectinib	DMMPTLH	Moderate	Increased risk of prolong QT interval by the combination of Norfloxacin and Entrectinib.	Non-small cell lung cancer [2C25]	[15]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of prolong QT interval by the combination of Norfloxacin and Levomethadyl Acetate.	Opioid use disorder [6C43]	[15]
Lofexidine	DM1WXA6	Moderate	Increased risk of prolong QT interval by the combination of Norfloxacin and Lofexidine.	Opioid use disorder [6C43]	[23]
Rucaparib	DM9PVX8	Moderate	Increased risk of prolong QT interval by the combination of Norfloxacin and Rucaparib.	Ovarian cancer [2C73]	[13]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Norfloxacin and Triclabendazole.	Parasitic worm infestation [1F90]	[21]
Rasagiline	DM3WKQ4	Moderate	Decreased metabolism of Norfloxacin caused by Rasagiline mediated inhibition of CYP450 enzyme.	Parkinsonism [8A00]	[21]
Pimavanserin	DMR7IVC	Moderate	Increased risk of prolong QT interval by the combination of Norfloxacin and Pimavanserin.	Parkinsonism [8A00]	[45]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Norfloxacin and Lefamulin.	Pneumonia [CA40]	[14]
Choline salicylate	DM8P137	Moderate	Additive CNS stimulant effects by the combination of Norfloxacin and Choline salicylate.	Postoperative inflammation [1A00-CA43]	[46]
Degarelix	DM3O8QY	Moderate	Increased risk of prolong QT interval by the combination of Norfloxacin and Degarelix.	Prostate cancer [2C82]	[15]
Enzalutamide	DMGL19D	Moderate	Increased risk of prolong QT interval by the combination of Norfloxacin and Enzalutamide.	Prostate cancer [2C82]	[15]
Relugolix	DMK7IWL	Moderate	Increased risk of prolong QT interval by the combination of Norfloxacin and Relugolix.	Prostate cancer [2C82]	[15]
Bicalutamide	DMZMSPF	Moderate	Increased risk of prolong QT interval by the combination of Norfloxacin and Bicalutamide.	Prostate cancer [2C82]	[15]
Levomepromazine	DMIKFEL	Moderate	Increased risk of prolong QT interval by the combination of Norfloxacin and Levomepromazine.	Psychotic disorder [6A20-6A25]	[21]
Salsalate	DM13P4C	Moderate	Additive CNS stimulant effects by the combination of Norfloxacin and Salsalate.	Rheumatoid arthritis [FA20]	[47]
Dexamethasone	DMMWZET	Major	Increased risk of tendinitis/tendon rupture by the combination of Norfloxacin and Dexamethasone.	Rheumatoid arthritis [FA20]	[43]
Quetiapine	DM1N62C	Moderate	Increased risk of prolong QT interval by the combination of Norfloxacin and Quetiapine.	Schizophrenia [6A20]	[23]
Aripiprazole	DM3NUMH	Moderate	Increased risk of prolong QT interval by the combination of Norfloxacin and Aripiprazole.	Schizophrenia [6A20]	[21]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Norfloxacin and Iloperidone.	Schizophrenia [6A20]	[23]
Paliperidone	DM7NPJS	Moderate	Increased risk of prolong QT interval by the combination of Norfloxacin and Paliperidone.	Schizophrenia [6A20]	[13]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Norfloxacin and Amisulpride.	Schizophrenia [6A20]	[48]
Asenapine	DMSQZE2	Moderate	Increased risk of prolong QT interval by the combination of Norfloxacin and Asenapine.	Schizophrenia [6A20]	[23]
Pimozide	DMW83TP	Major	Increased risk of prolong QT interval by the combination of Norfloxacin and Pimozide.	Schizophrenia [6A20]	[15]
Ifosfamide	DMCT3I8	Minor	Decreased absorption of Norfloxacin due to intestinal mucosa variation caused by Ifosfamide.	Solid tumour/cancer [2A00-2F9Z]	[22]
Docetaxel	DMDI269	Minor	Decreased absorption of Norfloxacin due to intestinal mucosa variation caused by Docetaxel.	Solid tumour/cancer [2A00-2F9Z]	[22]
Mitoxantrone	DMM39BF	Minor	Decreased absorption of Norfloxacin due to intestinal mucosa variation caused by Mitoxantrone.	Solid tumour/cancer [2A00-2F9Z]	[22]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Norfloxacin and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[23]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Norfloxacin and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[23]
Taxol	DMUOT9V	Minor	Decreased absorption of Norfloxacin due to intestinal mucosa variation caused by Taxol.	Solid tumour/cancer [2A00-2F9Z]	[22]
Pitolisant	DM8RFNJ	Moderate	Increased risk of prolong QT interval by the combination of Norfloxacin and Pitolisant.	Somnolence [MG42]	[15]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Norfloxacin and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[13]
Plicamycin	DM7C8YV	Minor	Decreased absorption of Norfloxacin due to intestinal mucosa variation caused by Plicamycin.	Testicular cancer [2C80]	[22]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Norfloxacin and Lenvatinib.	Thyroid cancer [2D10]	[13]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Norfloxacin and Cabozantinib.	Thyroid cancer [2D10]	[15]
Papaverine	DMCA9QP	Major	Increased risk of prolong QT interval by the combination of Norfloxacin and Papaverine.	Tonus and reflex abnormality [MB47]	[49]
Trimeprazine	DMEMV9D	Moderate	Increased risk of prolong QT interval by the combination of Norfloxacin and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[21]
Propafenone	DMPIBJK	Moderate	Increased risk of prolong QT interval by the combination of Norfloxacin and Propafenone.	Ventricular tachyarrhythmia [BC71]	[13]
Flecainide	DMSQDLE	Moderate	Increased risk of prolong QT interval by the combination of Norfloxacin and Flecainide.	Ventricular tachyarrhythmia [BC71]	[13]
Amiodarone	DMUTEX3	Major	Increased risk of prolong QT interval by the combination of Norfloxacin and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[50]
-----------


⏷ Show the Full List of 118 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Carmellose sodium	E00625	Not Available	Disintegrant
Magnesium stearate	E00208	11177	lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
--------------------

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Norfloxacin 400 mg tablet	400 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Norfloxacin FDA Label
2	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 074690.
3	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
5	Identification of influx transporter for the quinolone antibacterial agent levofloxacin. Mol Pharm. 2007 Jan-Feb;4(1):85-94.
6	Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion. Drug Metab Dispos. 2006 Apr;34(4):690-5.
7	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
8	Clinically significant psychotropic drug-drug interactions in the primary care setting. Curr Psychiatry Rep. 2012 Aug;14(4):376-90.
9	Norfloxacin induces apoptosis and necroptosis in human corneal epithelial cells. Toxicol In Vitro. 2020 Aug;66:104868. doi: 10.1016/j.tiv.2020.104868. Epub 2020 Apr 19.
10	Contrasting effects of fluoroquinolone antibiotics on the expression of the collagenases, matrix metalloproteinases (MMP)-1 and -13, in human tendon-derived cells. Rheumatology (Oxford). 2005 Dec;44(12):1514-7. doi: 10.1093/rheumatology/kei087. Epub 2005 Sep 7.
11	Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
12	Computational and experimental studies on the inhibitory mechanism of hydroxychloroquine on hERG. Toxicology. 2021 Jun 30;458:152822. doi: 10.1016/j.tox.2021.152822. Epub 2021 May 28.
13	Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
14	Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
15	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
16	Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
17	Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001): 301-19. [PMID: 11253855]
18	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
19	Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
20	Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986): 187-93. [PMID: 3542945]
21	Cerner Multum, Inc. "Australian Product Information.".
22	Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
23	Canadian Pharmacists Association.
24	Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
25	Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
26	Friedman CI, Huneke AL, Kim MH, Powell J "The effect of ampicillin on oral contraceptive effectiveness." Obstet Gynecol 55 (1980): 33-7. [PMID: 7188714]
27	Davis RL, Kelly HW, Quenzer RW, Standefer J, Steinberg B, Gallegos J "Effect of norfloxacin on theophyllin metabolism." Antimicrob Agents Chemother 33 (1989): 212-4. [PMID: 2719466]
28	Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
29	Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
30	Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
31	Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
32	Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
33	Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
34	Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A "Inhibition of norfloxacin absorption by antacids." Antimicrob Agents Chemother 34 (1990): 432-5. [PMID: 2334155]
35	Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
36	Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
37	Product Information. Retevmo (selpercatinib). Lilly, Eli and Company, Indianapolis, IN.
38	Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
39	Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
40	Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
41	Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
42	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
43	FDA. U.S. Food and Drug Administration "Information for Healthcare Professionals. Fluoroquinolone Antimicrobial Drugs. FDA Alert [7/8/2008].".
44	Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
45	Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
46	Davey PG "Overview of drug interactions with the quinolones." J Antimicrob Chemother 22(suppl c) (1988): 97-107. [PMID: 3053579]
47	Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
48	Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
49	Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
50	Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]